Role of Interleukin-1 Inhibitors Anakinra and Canakinumab in the treatment of Behcet's disease (BD)-related uveitis: A Retrospective Approach

Trial Profile

Role of Interleukin-1 Inhibitors Anakinra and Canakinumab in the treatment of Behcet's disease (BD)-related uveitis: A Retrospective Approach

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Anakinra (Primary) ; Canakinumab (Primary) ; Azathioprine; Methotrexate; Sulfasalazine
  • Indications Behcet's syndrome; Uveitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 25 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top